Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Share-based Compensation (2018 - 2025)

Organogenesis Holdings has reported Share-based Compensation over the past 8 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $4.3 million for Q4 2025, up 49.57% from a year ago — trailing twelve months through Dec 2025 was $13.3 million (up 25.71% YoY), and the annual figure for FY2025 was $13.3 million, up 25.71%.
  • Share-based Compensation for Q4 2025 was $4.3 million at Organogenesis Holdings, up from $3.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for ORGO hit a ceiling of $4.3 million in Q4 2025 and a floor of $698000.0 in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $2.3 million (2023), compared with a mean of $2.2 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 233.97% in 2021 and later fell 1.01% in 2025.
  • Organogenesis Holdings' Share-based Compensation stood at $1.1 million in 2021, then soared by 71.28% to $1.9 million in 2022, then rose by 27.55% to $2.4 million in 2023, then grew by 22.19% to $2.9 million in 2024, then surged by 49.57% to $4.3 million in 2025.
  • The last three reported values for Share-based Compensation were $4.3 million (Q4 2025), $3.1 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.